Expert Commentary

Managing menopausal symptoms in women with a BRCA mutation

OBG Manag. 2015 October;27(10)
By
Andrew M. Kaunitz, MD
Author and Disclosure Information

Dr. Andrew Kaunitz elaborates on data, presented at NAMS 2015, regarding the use of estrogen and estrogen-progestin in women undergoing risk-reducing gynecologic surgery. He offers his to-the-point advice for clinicians who are treating women with a BRCA mutation.

 

This audiocast was recorded at the North American Menopause Society Annual Meeting held September 30 to October 3, 2015, in Las Vegas, Nevada

For more on this topic, read Dr. Kaunitz's August 2015 Cases in Menopause article, Is menopausal hormone therapy safe when your patient carries a BRCA mutation?

Recommended Reading

ASCO: AIs reduce risk of contralateral breast cancer in patients with BRCA mutation
MDedge ObGyn
ASCO: MRI improved breast cancer detection in average risk women
MDedge ObGyn
ASCO: 80-gene profile pegs breast tumors resistant to trastuzumab
MDedge ObGyn
ASCO: Model predicts risk for breast cancer from atypical hyperplasia
MDedge ObGyn
ASCO: Many women with triple-negative breast cancer aren’t screened for BRCA
MDedge ObGyn
Computer-aided detection fails to improve mammographic accuracy
MDedge ObGyn
Two heads plus four hands equal safe, shorter bilateral mastectomies
MDedge ObGyn
Nipple-sparing mastectomy feasible in N+ early breast cancer
MDedge ObGyn
Get smart about dense breasts
MDedge ObGyn
VIDEO: When to use MRI in breast cancer
MDedge ObGyn

Related Articles